PAVmed

PAVmed Debt

The Debt of PAVmed (PAVM) as of Oct 20, 2026 is 13.35 M USD. In the previous year, Debt was 31.86 M USD — a change of -58.10% (lower).

Debt

13.35 MUSD

YoY

-58.10%

Last updated:

In 2025, PAVmed's total debt was 13.35 M USD, a -58.10% change from the 31.86 M USD total debt recorded in the previous year.

The PAVmed Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
3.89 M USD
Jan 1, 2018
7.90 M USD
Jan 1, 2019
8.14 M USD
Jan 1, 2020
14.96 M USD
Jan 1, 2022
36.64 M USD
Jan 1, 2023
48.73 M USD
Jan 1, 2024
31.86 M USD
Jan 1, 2025
13.35 M USD
The PAVmed Debt history
YEARDebtYoY
13.35 MUSD-58.10%
31.86 MUSD-34.61%
48.73 MUSD+32.99%
36.64 MUSD+144.90%
14.96 MUSD+83.81%
8.14 MUSD+2.99%
7.90 MUSD+103.24%
3.89 MUSD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PAVmed Stock analysis

What does PAVmed do? PAVmed, Inc. generates revenue through the development and commercialization of medical devices including PortIO, a vascular access device without central venous system access or indwelling intravascular components, and CarpX, a percutaneous device for carpal tunnel syndrome treatment. The company also offers NextCath, a self-anchoring catheter eliminating the need for suturing or traditional anchoring methods, and DisappEAR, antibiotic-eluting resorbable ear tubes utilizing aqueous silk technology. Additional products include NextFlo, a disposable infusion system with variable flow resistors, and Caldus, a disposable tissue ablation device. Medical device companies and healthcare providers purchase these products for patient treatment and surgical procedures. The firm's product portfolio targets specific medical needs such as vascular access, orthopedic procedures, and ear treatments. PortIO serves patients requiring long-term vascular access without traditional central line risks. CarpX addresses carpal tunnel syndrome through minimally invasive procedures. DisappEAR provides a solution for ear tube insertion using resorbable technology, reducing the need for follow-up surgeries. NextCath streamlines catheter placement in medical settings. PAVmed's commercial strategy focuses on medical device companies and healthcare providers seeking innovative solutions for vascular access, orthopedic interventions, and ear care. The company's products are designed to improve patient outcomes while reducing procedural complexity and costs. By leveraging proprietary technologies like aqueous silk for DisappEAR, PAVmed differentiates its offerings in the medical device market. PAVmed is one of the most popular companies on Eulerpool.

Debt Details

Understanding PAVmed's Debt Structure

PAVmed's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing PAVmed's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to PAVmed’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in PAVmed’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about PAVmed stock

Debt of PAVmed is 13.35 M USD in 2025.

Debt of PAVmed changed from 31.86 M USD to 13.35 M USD, representing a -58.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt PAVmed since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's PAVmed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PAVmed

All Key Metrics — PAVmed